Novamed holds a firm place on the market of urinalysis products and continues to be in the lead of the local market of medical diagnostic and research products. 

Novamed’s DipStreak®/ChromoStreak®/Diaslide® urine culture devices are the type of bed-site devices for fast and simple UTI diagnosis. This is a novel method of isolation, counting and direct/presumptive identification of bacterial contamination in urine based on the color differences between colonies. 

The use of urine culture devices in doctor’s offices, private clinics, hospitals and out-patient communities completely changes the concept of urine examination and allows to save both patient’s and personnel’s time. Additionally, the cost of the test is considerably reduced. DipStreak®/ChromoStreak®/Diaslide® are already FDA approved, CE marked and successfully used in many countries in all over the world including Israel, Russia, Ukraine, Italy, USA and Japan. 

Novamed’s production list for rapid immunodiagnostic products consists of more than 40 different items, intended for rapid diagnosis of infectious diseases and different physiological conditions in humans. The end user sector is represented by the clinical laboratories, emergency rooms, and doctor’s offices in Israel, Italy, Germany, Belgium, Ireland, Poland, Czech Republic, Switzerland, Lithuania, Kenya, Russia, Moldova, Belarus, Georgia, and Ukraine.

The Uni-Sep line of products has modernized procedures for lymphocyte isolation and separation. 

Currently, Novamed is successfully developing a new line of home-use Digital Health tests, allowing digital transmission of the results to personnel.

​

Novamed Ltd is a leading provider of innovative medical products. Our extensive product portfolio includes over 250 unique items, some of which are exclusive inventions in the market. We adhere to rigorous Quality Control standards, complying with ISO 13485:2016 and ISO 9001:2015.
With three main production lines specializing in microbiology culture media products, diagnostic products, and research products, we cater to diverse healthcare needs. Our microbiology culture media line alone consists of over 170 formulations, supporting microbial screening, identification, and antibiotic susceptibility testing in clinical labs. 
At Novamed, we are committed to advancing healthcare by delivering reliable, high-quality products that make a positive impact in the industry.​

Novamed is a leading company with 25 years of experience in developing, manufacturing, and marketing smart solutions for diagnostic testing of body fluids.
Novamed's solutions and platforms enable diagnosis at both treatment points and professional laboratories. The company has a manufacturing plant that complies with ISO 13485 and markets its products to various customers in Israel and around the world.
Some of the company's products are also approved by the European Union (CE) and the US FDA. The company's products are approved by both the Israeli and American health ministries.
Novamed is owned by Simplivia, which develops, manufactures, and markets technological systems for the preparation and administration of hazardous drugs that provide protection for medical staff and patients. Simplivia is approved by the FDA and is part of the portfolio of the FIMI Venture Capital Fund, considered the leading investment fund in Israel with around 80 companies.​
 

Novamed holds a firm place on the market of urinalysis products and continues to be in the lead of the local market of medical diagnostic and research products. Novamed’s DipStreak®/ChromoStreak®/Diaslide® urine culture devices are the type of bed-site devices for fast and simple UTI diagnosis. This is a novel method of isolation, counting and direct/presumptive identification of bacterial contamination in urine based on the color differences between colonies. The use of urine culture devices in doctor’s offices, private clinics, hospitals and out-patient communities completely changes the concept of urine examination and allows to save both patient’s and personnel’s time. Additionally, the cost of the test is considerably reduced. DipStreak®/ChromoStreak®/Diaslide® are already FDA approved, CE marked and successfully used in many countries in all over the world including Israel, Russia, Ukraine, Italy, USA and Japan. 

ABOUT US

Novamed’s production list for rapid immunodiagnostic products consists of more than 40 different items, intended for rapid diagnosis of infectious diseases and different physiological conditions in humans. The end user sector is represented by the clinical laboratories, emergency rooms, and doctor’s offices in Israel, Italy, Germany, Belgium, Ireland, Poland, Czech Republic, Switzerland, Lithuania, Kenya, Russia, Moldova, Belarus, Georgia, and Ukraine.The Uni-Sep line of products has modernized procedures for lymphocyte isolation and separation. Currently, Novamed is successfully developing a new line of home-use Digital Health tests, allowing digital transmission of the results to personnel.Novamed holds a firm place on the market of urinalysis products and continues to be in the lead of the local market of medical diagnostic and research products. Novamed’s DipStreak®/ChromoStreak®/Diaslide® urine culture devices are the type of bed-site devices for fast and simple UTI diagnosis. This is a novel method of isolation, counting and direct/presumptive identification of bacterial contamination in urine based on the color differences between colonies. The use of urine culture devices in doctor’s offices, private clinics, hospitals and out-patient communities completely changes the concept of urine examination and allows to save both patient’s and personnel’s time. Additionally, the cost of the test is considerably reduced. DipStreak®/ChromoStreak®/Diaslide® are already FDA approved, CE marked and successfully used in many countries in all over the world including Israel, Russia, Ukraine, Italy, USA and Japan. Novamed’s production list for rapid immunodiagnostic products consists of more than 40 different items, intended for rapid diagnosis of infectious diseases and different physiological conditions in humans. The end user sector is represented by the clinical laboratories, emergency rooms, and doctor’s offices in Israel, Italy, Germany, Belgium, Ireland, Poland, Czech Republic, Switzerland, Lithuania, Kenya, Russia, Moldova, Belarus, Georgia, and Ukraine.The Uni-Sep line of products has modernized procedures for lymphocyte isolation and separation. Currently, Novamed is successfully developing a new line of home-use Digital Health tests, allowing digital transmission of the results to personnel.​